Cytoki Pharma doses first patient in Phase 2 study of CK-0045 for obesity and T2DM
Cytoki Pharma has announced the first patient has received CK-0045 in a Phase 2 proof-of-concept trial evaluating efficacy, safety and...
top of page
Browse by category
Search
Positive Phase 1 data shows potential of CK-0045 to improve cardiometabolic risk factors
Cytoki Pharma has revealed positive data from a Phase 1 study evaluating the safety, tolerability and pharmacokinetics of CK-0045, its...
Browse by tag
bottom of page